- Goorin AM,
Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R
and Lipshultz SE.: Initial congestive
heart failure, six to ten years after
doxo-Rubicin chemotherapy for childhood cancer.
Jour Pediatrics 1990;116:144.
- Anselmi
Chavez G, Machado Hernandez I, Febres Ollarve C,
y Mathison Natera, Y.: Myocardial
protection by l-carnitine in children treated
with adriamycin. Rev Lat Cardiol 1997; 18:208.
- Anselmi G,
Strauss M, Chazzin G, Eleizalde G, Machado H I,
Pulido C.:Adriamycin cardiotoxicity. An
experimental, diagnostic, treatment and
prevention study. World Congress of Pediatric
Cardiology and Surgery,Satellite Symposium. Paris
June , 1993.
- Neri B,
Comparini T, Miliani A, Torcia M.: Protective
effect of l-carnitine on acute adriamycin and
daunomycin cardiotoxicity in cancer patients.Clin
Trials J. 1983; 20:98.
- Billinghan
ME, Bristow RW.: Evaluation of
anthracycline cardiotoxicity:Predictive ability
and functional correlation of endomyocardial
biopsy Cancer Treat Symp. Vol 3, 1984.
- Berg SL,
Balis FM, Poplack L et. al. The use of
cardioprotectant agents in combination with
anthracycline chemotherapy. 2d International
Conference on Long-Term Complications of
Treatment of Children and Adolerscents for
Cancer. June 12-14, 1992. Hyatt Regency Hotel,
Buffalo, NY.
- Neri G,
Cini-Neri G, Bandinelli M.: Differences
between carnitine derivatives and coenzyme Q-10
in preventing in vitro doxorubicyn related
cardiac damages . Oncology 1988; 45:242.
- Strauss M,
Anselmi G, Hermoso T, Tejero F.: Carnitine
promotes heat shock protein synthesis in
adriamycin-induced cardiomyopathy in a neonatal
heart experimental model. J Mol Cell Cardiol
1998; 30:2319.
|
